Mutation Analysis Of Selected Lymphoid Immune Disorders

特定淋巴免疫性疾病的突变分析

基本信息

  • 批准号:
    8952838
  • 负责人:
  • 金额:
    --
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
  • 资助国家:
    美国
  • 起止时间:
  • 项目状态:
    未结题

项目摘要

This project represents is a continuation of series of collaborative studies performed to better characterize and understand immune deficiency. Mutations involving the genes for the common gamma chain (X-SCID) and Fas (ALPS) are being evaluated using Sanger sequencing of genomic DNA with fluorescent probes. These studies have continued to identify a number of new mutations in both diseases and these data have been entered into the NIH NHGRI web site supporting each of these two disorders. This was followed by the inclusion of mutation analysis of patients with hyper IgM syndrome directed at the genes encoding CD40L and NEMO followed by sequencing for immune deficiency associated mutations focused on host defense defects with recurrent infections involving opportunisitc intracellular organisms including genes encoding the interferon gamma receptor 1 and 2, the IL-12P40 and IL-12 receptor beta 1 genes. Finally, new additional genes have been added to the repertoire including genes encoding: AIRE, ARTEMIS, BTK, FOXP3, ICOS, IL-7Ralpha, JAK3, mu heavy chain,SAP, WASp. This initial work is now complemented by NextGen sequencing using the Ion Torrent PGM platform focused on expanding number of genes evaluated associated with primary immunodeficiencies that currently is focused on 172 known or possible primary immunodeficiency genes to screen patients refered to the NIH and on clinical research protocols with suspected primary immunodeficiency disorders. THis approach to gene mutation screeningd depends on emulsion PCR platform (Haloplex system) that has been validated in house. This togetehr with the choice of the appropriate library has been validated using deidentified patient gDNA samples with previously defined mutations linked to primary immunodeficiency disorders. To date we have identified at least a number of new genes associated with a previously uncharacterized primary immunodeficiency that have been confirmed by Sanger sequencing and functional testing. We continue to evaluate additional samples and will be moving to a more robust platform using the same principle but potentially allowing whole exome sequencing as well as targeted gene sequencing. We are in the process of preparing for publication our overall experience with the targeted gene approach (using the Ion Torrent and Haloplex technology) in screening a substantial number of patient samples. Our expereince to date suggests that this is a cost effective approach for screening referred patients with clear evidence of defects in host defense and that resequencing using the standard Sanger method under defined circumstances smay not be necessary.
该项目是一系列合作研究的延续,旨在更好地表征和理解免疫缺陷。使用荧光探针对基因组DNA进行桑格测序,评价涉及共同γ链(X-SCID)和Fas(ALPS)基因的突变。这些研究继续在这两种疾病中鉴定出许多新的突变,这些数据已输入NIH NHGRI网站,支持这两种疾病中的每一种。 随后纳入了针对编码CD 40 L和NEMO的基因的高IgM综合征患者的突变分析,随后对免疫缺陷相关突变进行测序,重点关注涉及机会性细胞内生物体的复发性感染的宿主防御缺陷,包括编码干扰素γ受体1和2、IL-12 P40和IL-12受体β 1基因的基因。最后,新的额外基因已被添加到库中,包括编码以下的基因:AIRE、ARTEMIS、BTK、FOXP 3、ICOS、IL-7 Ra、JAK 3、mu重链、SAP、WASp。这项初步工作现在得到了NextGen测序的补充,NextGen测序使用Ion Torrent PGM平台,专注于扩大与原发性免疫缺陷相关的基因数量,目前专注于172个已知或可能的原发性免疫缺陷基因,以筛选NIH和疑似原发性免疫缺陷疾病的临床研究方案的患者。这种基因突变筛查方法依赖于已在内部验证的乳液PCR平台(Haloplex系统)。这与适当文库的选择一起已经使用具有先前定义的与原发性免疫缺陷病症相关的突变的去识别患者gDNA样品进行了验证。到目前为止,我们已经确定了至少一些新的基因与以前未表征的原发性免疫缺陷,已证实由桑格测序和功能测试。我们将继续评估更多的样本,并将使用相同的原则转向更强大的平台,但可能允许全外显子组测序以及靶向基因测序。我们正在准备出版我们在筛选大量患者样本中使用靶向基因方法(使用Ion Torrent和Haloplex技术)的总体经验。我们迄今为止的经验表明,这是一种具有成本效益的方法,用于筛选有明确证据表明宿主防御缺陷的转诊患者,并且在规定的情况下使用标准桑格方法重新测序可能是不必要的。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

thomas a fleisher其他文献

thomas a fleisher的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('thomas a fleisher', 18)}}的其他基金

ASSESSMENT OF PERIPHERAL BLOOD EOSINOPHILS
外周血嗜酸性粒细胞的评估
  • 批准号:
    6289480
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
Assessment Of Memory B Cells In Immune Disorders
免疫疾病中记忆 B 细胞的评估
  • 批准号:
    6825555
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
Assessment of Hydrogen Peroxide Generation in Neutrophils
中性粒细胞中过氧化氢生成的评估
  • 批准号:
    6431837
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
ASSESSMENT OF MEMORY B CELLS IN IMMUNE DISORDERS
免疫疾病中记忆 B 细胞的评估
  • 批准号:
    6414335
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
Mutation Analysis of Selected Lymphoid Immune Disorders
特定淋巴免疫性疾病的突变分析
  • 批准号:
    6431867
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
Assessment of Peripheral Blood Monocytes in Patients with Recurrent Mycobacterial
复发性分枝杆菌患者外周血单核细胞的评估
  • 批准号:
    6103714
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
Mutation Analysis Of Selected Lymphoid Immune Disorders
特定淋巴免疫性疾病的突变分析
  • 批准号:
    8565338
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
ASSESSMENT OF LYMPHOCYTES IN PATIENTS WITH AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROM
自身免疫性淋巴细胞增殖综合征患者的淋巴细胞评估
  • 批准号:
    6289482
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
ASSESSMENT OF HYDROGEN PEROXIDE GENERATION IN NEUTROPHILS
中性粒细胞中过氧化氢生成的评估
  • 批准号:
    6289456
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
Assessment Of Lymphocytes In Patients With Autoimmune Ly
自身免疫性 Ly 患者淋巴细胞的评估
  • 批准号:
    6675210
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了